Literature DB >> 30177066

Clinical implementation of the sFlt-1/PlGF ratio to identify preeclampsia and fetal growth restriction: A prospective cohort study.

I Herraiz1, E Simón2, P I Gómez-Arriaga2, M S Quezada2, A García-Burguillo2, E A López-Jiménez3, A Galindo2.   

Abstract

OBJECTIVE: To analyze the usefulness of a clinical protocol for early detection of preeclampsia and/or fetal growth restriction (PE/FGR) using, in previously selected pregnancies, the measurement of the sFlt-1/PlGF ratio at 24-28 weeks of gestation. STUDY
DESIGN: Prospective observational cohort study carried out in a single tertiary hospital in Spain. 5601 consecutive singleton pregnancies with complete follow-up were included. High-risk women for PE/FGR were selected by combining data from maternal history and second trimester uterine artery Doppler. Subsequently these patients underwent intensive monitoring, including the measurement of the sFlt-1/PlGF ratio at 24-28 weeks to predict PE/FGR. MAIN OUTCOME MEASURES: Early, intermediate and late PE/FGR (delivery <32 + 0, 32 + 0 - <36 + 0 and ≥36 + 0 weeks, respectively).
RESULTS: Overall incidence of early, intermediate and late PE/FGR was 0.3%, 0.7% and 3.2%, respectively, being higher in the 4.3% of women selected for intensive monitoring: 5.8%, 8.7% and 15.4%, respectively (all p < 0.001). The area under the curve (AUC) with 95%CI of the sFlt-1/PlGF ratio for detecting early PE/FGR was 0.98 (0.97-1.00), and the sFlt-1/PlGF ratio >95th centile showed a sensitivity (%) of 100 (95%CI, 78.5-100) and specificity (%) of 80.6 (95%CI, 75.0-85.2). The AUC of the sFlt-1/PlGF ratio for detecting intermediate and late PE/FGR was of 0.87 (95%CI, 0.77-0.97) and 0.68 (95%CI, 0.58-0.79), respectively.
CONCLUSION: A contingent strategy of measuring the sFlt-1/PlGF ratio at 24-28 weeks in women previously selected by clinical factors and uterine artery Doppler enables an accurate prediction of PE/FGR. This performance is optimal to predict PE/FGR requiring delivery before 32 weeks.
Copyright © 2018 International Society for the Study of Hypertension in Pregnancy. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Fetal growth restriction; PlGF; Preeclampsia; sFlt-1

Mesh:

Substances:

Year:  2018        PMID: 30177066     DOI: 10.1016/j.preghy.2018.06.017

Source DB:  PubMed          Journal:  Pregnancy Hypertens        ISSN: 2210-7789            Impact factor:   2.899


  8 in total

1.  High early pregnancy body mass index is associated with alterations in first- and second-trimester angiogenic biomarkers.

Authors:  Celeste Beck; Amanda Allshouse; Robert M Silver; William A Grobman; Hyagriv Simhan; David Haas; Uma M Reddy; Nathan R Blue
Journal:  Am J Obstet Gynecol MFM       Date:  2022-03-10

2.  The role and mechanism of asymmetric dimethylarginine in fetal growth restriction via interference with endothelial function and angiogenesis.

Authors:  Yan Dai; Jun Zhang; Rong Liu; Na Xu; Song-Biao Yan; Yi Chen; Tian-He Li
Journal:  J Assist Reprod Genet       Date:  2020-03-25       Impact factor: 3.412

3.  Maternal omega-3 fatty acids and vitamin E improve placental angiogenesis in late-onset but not early-onset preeclampsia.

Authors:  Vaishali Kasture; Deepali Sundrani; Surabhi Dalvi; Mayur Swamy; Anvita Kale; Sadhana Joshi
Journal:  Mol Cell Biochem       Date:  2019-08-16       Impact factor: 3.842

4.  Maternal placental growth factor and soluble fms-like tyrosine kinase-1 reference ranges in post-term pregnancies: A prospective observational study.

Authors:  Birgitte Mitlid-Mork; Sophie Bowe; Jon M Gran; Nils Bolstad; Jens Petter Berg; Christopher W Redman; Anne Cathrine Staff; Meryam Sugulle
Journal:  PLoS One       Date:  2020-10-20       Impact factor: 3.240

5.  Quantitative proteomic analysis of serum-purified exosomes identifies putative pre-eclampsia-associated biomarkers.

Authors:  Rosana Navajas; Antonio Ramos-Fernandez; Ignacio Herraiz; Alberto Galindo; José Luis Bartha; Fernando Corrales; Alberto Paradela
Journal:  Clin Proteomics       Date:  2022-02-10       Impact factor: 3.988

6.  The effect of nicotine-containing products and fetal sex on placenta-associated circulating midpregnancy biomarkers.

Authors:  Birgitte Kordt Sundet; Ina Kreyberg; Anne Cathrine Staff; Karin Cecilie Lødrup Carlsen; Karen Eline Stensby Bains; Jens Petter Berg; Berit Granum; Guttorm Haugen; Gunilla Hedlin; Christine Monceyron Jonassen; Live Solveig Nordhagen; Björn Nordlund; Eva Maria Rehbinder; Knut Rudi; Corina Silvia Rueegg; Katrine Dønvold Sjøborg; Håvard Ove Skjerven; Cilla Söderhäll; Riyas Vettukattil; Meryam Sugulle
Journal:  Biol Sex Differ       Date:  2022-07-15       Impact factor: 8.811

7.  Increased Angiogenesis and Lymphangiogenesis in the Placental Villi of Women with Chronic Venous Disease during Pregnancy.

Authors:  Miguel A Ortega; Miguel A Saez; Oscar Fraile-Martínez; Ángel Asúnsolo; Leonel Pekarek; Coral Bravo; Santiago Coca; Felipe Sainz; Melchor Álvarez- Mon; Julia Buján; Natalio García-Honduvilla
Journal:  Int J Mol Sci       Date:  2020-04-03       Impact factor: 5.923

8.  Maternal and Perinatal Outcomes Associated With Extremely High Values for the sFlt-1 (Soluble fms-Like Tyrosine Kinase 1)/PlGF (Placental Growth Factor) Ratio.

Authors:  Cecilia Villalaín; Ignacio Herraiz; Leonor Valle; Manel Mendoza; Juan Luis Delgado; María Vázquez-Fernández; Juan Martínez-Uriarte; Íñigo Melchor; Sara Caamiña; Antoni Fernández-Oliva; Olga Patricia Villar; Alberto Galindo
Journal:  J Am Heart Assoc       Date:  2020-04-04       Impact factor: 5.501

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.